Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation

Rahul H. Damani; Jose I. Suarez

doi:10.14423/SMJ.0000000000000552

Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation

Rahul H. Damani, Jose I. Suarez

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Approximately 750,000 US adults per year experience a stroke. On average, the annual risk for future ischemic stroke (secondary stroke) after an initial ischemic stroke or transient ischemic attack is approximately 3% to 4%. Cardioembolic strokes account for 20% to 25% of all strokes, with nonvalvular atrial fibrillation (NVAF) considered one of the main sources of embolism; this explains up to half of all cardioembolic strokes. We present the risk factors for stroke in NVAF, risk stratification, a diagnosis of NVAF, and treatment and prevention of stroke in NVAF. We reviewed the literature by performing a PubMed search of articles focusing on secondary stroke prevention in NVAF. This review examines the findings of major clinical trials and society guidelines for secondary stroke prevention in NVAF and presents a cost-effectiveness analysis.

Original language	English (US)
Pages (from-to)	721-729
Number of pages	9
Journal	Southern medical journal
Volume	109
Issue number	11
DOIs	https://doi.org/10.14423/SMJ.0000000000000552
State	Published - Nov 1 2016
Externally published	Yes

Keywords

cardioembolic stroke
nonvalvular atrial fibrillation
novel anticoagulants
oral anticoagulation
warfarin

ASJC Scopus subject areas

General Medicine

Access to Document

10.14423/SMJ.0000000000000552

Cite this

@article{1bdd8157ebdd4212bac54a3e91450ae2,

title = "Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation",

abstract = "Approximately 750,000 US adults per year experience a stroke. On average, the annual risk for future ischemic stroke (secondary stroke) after an initial ischemic stroke or transient ischemic attack is approximately 3% to 4%. Cardioembolic strokes account for 20% to 25% of all strokes, with nonvalvular atrial fibrillation (NVAF) considered one of the main sources of embolism; this explains up to half of all cardioembolic strokes. We present the risk factors for stroke in NVAF, risk stratification, a diagnosis of NVAF, and treatment and prevention of stroke in NVAF. We reviewed the literature by performing a PubMed search of articles focusing on secondary stroke prevention in NVAF. This review examines the findings of major clinical trials and society guidelines for secondary stroke prevention in NVAF and presents a cost-effectiveness analysis.",

keywords = "cardioembolic stroke, nonvalvular atrial fibrillation, novel anticoagulants, oral anticoagulation, warfarin",

author = "Damani, {Rahul H.} and Suarez, {Jose I.}",

year = "2016",

month = nov,

day = "1",

doi = "10.14423/SMJ.0000000000000552",

language = "English (US)",

volume = "109",

pages = "721--729",

journal = "Southern medical journal",

issn = "0038-4348",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation

AU - Damani, Rahul H.

AU - Suarez, Jose I.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Approximately 750,000 US adults per year experience a stroke. On average, the annual risk for future ischemic stroke (secondary stroke) after an initial ischemic stroke or transient ischemic attack is approximately 3% to 4%. Cardioembolic strokes account for 20% to 25% of all strokes, with nonvalvular atrial fibrillation (NVAF) considered one of the main sources of embolism; this explains up to half of all cardioembolic strokes. We present the risk factors for stroke in NVAF, risk stratification, a diagnosis of NVAF, and treatment and prevention of stroke in NVAF. We reviewed the literature by performing a PubMed search of articles focusing on secondary stroke prevention in NVAF. This review examines the findings of major clinical trials and society guidelines for secondary stroke prevention in NVAF and presents a cost-effectiveness analysis.

AB - Approximately 750,000 US adults per year experience a stroke. On average, the annual risk for future ischemic stroke (secondary stroke) after an initial ischemic stroke or transient ischemic attack is approximately 3% to 4%. Cardioembolic strokes account for 20% to 25% of all strokes, with nonvalvular atrial fibrillation (NVAF) considered one of the main sources of embolism; this explains up to half of all cardioembolic strokes. We present the risk factors for stroke in NVAF, risk stratification, a diagnosis of NVAF, and treatment and prevention of stroke in NVAF. We reviewed the literature by performing a PubMed search of articles focusing on secondary stroke prevention in NVAF. This review examines the findings of major clinical trials and society guidelines for secondary stroke prevention in NVAF and presents a cost-effectiveness analysis.

KW - cardioembolic stroke

KW - nonvalvular atrial fibrillation

KW - novel anticoagulants

KW - oral anticoagulation

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84994236172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994236172&partnerID=8YFLogxK

U2 - 10.14423/SMJ.0000000000000552

DO - 10.14423/SMJ.0000000000000552

M3 - Article

C2 - 27812719

AN - SCOPUS:84994236172

SN - 0038-4348

VL - 109

SP - 721

EP - 729

JO - Southern medical journal

JF - Southern medical journal

IS - 11

ER -

Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this